Medical device prices in Japan are adjusted periodically through NHI fee schedule revisions, managed by MHLW & Chuikyo. Adjustments account for market trends, technological advancements, competition, & cost-effectiveness. If a device’s price significantly decreases in the market, its reimbursement price may be... Read More
Japan’s reimbursement policies are updated annually through MHLW, with input from Chuikyo. These updates revise the NHI fee schedule, adjust pricing for medical devices based on market trends & clinical value, & may introduce new categories or reimbursement criteria. The goal is... Read More
Japan determines the cost-effectiveness of medical devices through Health Technology Assessment (HTA), overseen by MHLW & Chuikyo. Manufacturers submit clinical & economic evidence, including cost-benefit analyses & quality-adjusted life years (QALYs). Devices are evaluated for their impact on healthcare outcomes & costs,... Read More
The Chuikyo committee plays a central role in Japan’s medical device reimbursement by reviewing applications, classifying devices, & determining reimbursement prices. It evaluates clinical efficacy, safety, cost-effectiveness, & healthcare system impact. Chuikyo ensures fair pricing, aligns devices with NHI standards, & supports... Read More
The fee-for-service model in Japan’s reimbursement system compensates healthcare providers based on individual services rendered, including medical device usage. Each service or procedure is assigned a fixed fee under the National Health Insurance (NHI) fee schedule, determined by MHLW & Chuikyo. This... Read More
Japan evaluates combination medical products—those integrating drugs, devices, or biologics—based on their primary mode of action. MHLW determines regulatory pathways & reimbursement classification, with Chuikyo assessing clinical benefits, safety, & cost-effectiveness. Reimbursement aligns with the National Health Insurance (NHI) system, often requiring... Read More
Post-market surveillance for reimbursed devices in Japan requires manufacturers to monitor safety, efficacy, & performance. They must report adverse events, submit periodic safety updates, & conduct post-marketing studies if mandated. Compliance with PMDA & MHLW regulations ensures devices maintain their approved reimbursement... Read More
The pricing process for medical devices reimbursed in Japan involves Chuikyo evaluating the device’s clinical benefits, safety, & cost-effectiveness. Pricing is set by comparing similar devices (reference pricing) or using cost-based calculations. Devices with innovative features may qualify for premium pricing. Approved... Read More
Japan handles reimbursement for digital health devices through the MHLW & Chuikyo. These devices must demonstrate clinical efficacy, safety, & cost-effectiveness. They are classified under existing categories or evaluated for new classifications. Evidence from clinical trials or real-world data is essential, &... Read More
Reimbursement approval in Japan typically takes 6-12 months after regulatory approval. The process involves submitting an application to MHLW, Chuikyo review for classification & pricing, & listing in the NHI fee schedule. The timeline varies based on device complexity, evidence quality, &... Read More